Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neck

A tumor-agnostic plasma ctDNA assay detected MRD after curative-intent treatment in locally advanced SCCHN and stratified 2-year PFS (23.5% if MRD-positive vs 86.6% if MRD-negative).

Ann OncolPubMed 37879442DOI 10.1016/j.annonc.2023.09.3102